Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应子的机制分析
基本信息
- 批准号:8623095
- 负责人:
- 金额:$ 24.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAntiviral AgentsBiochemicalBiological AssayBiologyCellsCellular MembraneChemicalsComplexCysteineDataDevelopmentDiseaseEnzymesEpithelial CellsFamilyGenesGeneticGoalsHandHealthHemagglutininHost DefenseImmunityInfectionInfluenzaIntegral Membrane ProteinInterferon Type IInterferonsKnowledgeLipidsLungLysineMapsMeasuresMembraneMentorsMethodsMicroscopyModificationNatural ImmunityNeurodegenerative DisordersOutcomePhasePhysiologyPlayPolyubiquitinPost-Translational Protein ProcessingPrevention strategyProteinsRecyclingRegulationReporterResearchRoleSignal TransductionSiteTestingTherapeuticTranscriptional RegulationUbiquitinationVaccine TherapyViralViral ProteinsVirionVirusVirus Diseasesbasecell growth regulationcombatcytokineinfluenzavirusinsightmutantnovelpalmitoylationparticlepathogenpreventprotein acyltransferaseresearch studytrafficking
项目摘要
Influenza and other emerging viruses represent major health concerns worldwide, and current strategies for
prevention or treatment of disease are insufficient. Type I interferon is a cytokine that induces an antiviral state
in cells by transcriptionally upregulating hundreds of genes. Some of these genes encode proteins with direct
antiviral activity, though only a small number of these proteins have been mechanistically characterized.
Among these proteins, the interferon-inducible transmembrane protein 3 (IFITM3) has been recently shown by
us and others to have broad antiviral activity against all subtypes of influenza virus tested as well as a number
of other virus families. Furthermore, this protein is unique among interferon effectors in that it appears to act
by preventing entry or fusion of viruses rather than inhibiting viral replication. Using chemical reporters, we
have shown that IFITM3 is post-translationally palmitoylated and this lipid modification regulates its antiviral
activity. Furthermore, our preliminary data indicate that IFITM3 is also ubiquitinated. The overall goal of the
proposed research is to increase understanding of innate antiviral immunity by characterizing the mechanism
of action of IFITM3 and its cellular regulation by post-translational modifications. In the K99 phase, we will
develop biochemical and microscopy assays to test the hypothesis that palmitoylation controls proper
trafficking of IFITM3 allowing it to interact with viral particles and prevent viral entry. With this knowledge in
hand we will then seek in the R00 phase to identify enzymes responsible for IFITM3 palmitoylation and look at
the global transcriptional regulation of palmitoylating enzymes during viral infections. Furthermore, we will
apply assays developed in the K99 phase to understand the role of ubiquitination in IFITM3 biology and its
interplay with palmitoylation. Analyzing the mechanism of action of IFITM3 and the control of this activity by a
unique set of post-translational modifications may provide insights necessary for harnessing the power of type I
interferon for combating viral pathogens.
流感和其他新出现的病毒代表了世界范围内的主要健康问题,
疾病的预防或治疗是不够的。I型干扰素是一种诱导抗病毒状态的细胞因子
在细胞中通过转录上调数百个基因。这些基因中的一些编码蛋白质,
抗病毒活性,尽管这些蛋白质中只有一小部分已经被机械地表征。
在这些蛋白质中,干扰素诱导型跨膜蛋白3(IFITM3)最近已被证明是由
美国和其他国家对所有测试的流感病毒亚型以及一些
其他病毒家族。此外,这种蛋白质在干扰素效应物中是独特的,因为它似乎起作用于
通过阻止病毒进入或融合而不是抑制病毒复制。使用化学报告,我们
已经表明IFITM3是后脂肪棕榈酰化的,这种脂质修饰调节其抗病毒活性,
活动此外,我们的初步数据表明IFITM3也是泛素化的。的总体目标
拟议的研究是通过描述机制来增加对先天抗病毒免疫的理解,
IFITM3的作用及其通过翻译后修饰的细胞调节。在K99阶段,
开发生物化学和显微镜分析,以测试棕榈酰化控制适当的假设,
IFITM3的运输允许其与病毒颗粒相互作用并防止病毒进入。有了这些知识,
另一方面,我们将在R00阶段寻找鉴定负责IFITM3棕榈酰化的酶,并观察
病毒感染期间棕榈酰化酶的整体转录调节。此外,我们将
应用在K99阶段开发的测定来了解泛素化在IFITM3生物学中的作用及其
与棕榈酰化相互作用。分析IFITM3的作用机制和通过一种新的方法来控制这种活性。
一组独特的翻译后修饰可能为利用I型糖尿病的力量提供必要的见解,
干扰素用于对抗病毒病原体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacob Yount其他文献
Jacob Yount的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacob Yount', 18)}}的其他基金
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10597869 - 财政年份:2023
- 资助金额:
$ 24.45万 - 项目类别:
Establishing a relevant mouse model with susceptibility to non-adapted influenza viruses for vaccine challenge studies
建立对非适应性流感病毒易感的相关小鼠模型,用于疫苗攻击研究
- 批准号:
10211108 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10531244 - 财政年份:2017
- 资助金额:
$ 24.45万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
9288927 - 财政年份:2017
- 资助金额:
$ 24.45万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10367235 - 财政年份:2017
- 资助金额:
$ 24.45万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10084253 - 财政年份:2017
- 资助金额:
$ 24.45万 - 项目类别:
Molecular Control of IFITM3 in Restricting Influenza Virus Infection
IFITM3 在限制流感病毒感染中的分子控制
- 批准号:
9012283 - 财政年份:2015
- 资助金额:
$ 24.45万 - 项目类别:
Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应器的机制分析
- 批准号:
8165228 - 财政年份:2011
- 资助金额:
$ 24.45万 - 项目类别:
Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应器的机制分析
- 批准号:
8601556 - 财政年份:2011
- 资助金额:
$ 24.45万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 24.45万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 24.45万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 24.45万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 24.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 24.45万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别: